ENANTIOS is an ETH Zürich deep‑tech spin‑off that commercializes a laser‑spectroscopy molecular characterization method based on Raman Optical Activity (ROA). The technology, developed over a five‑year research project at ETH Zurich, enables complete characterization of complex molecules and aspects of three‑dimensional structure not resolvable with other methods. ENANTIOS offers pharmaceutical companies and complex chemical providers data and insights intended to accelerate development of structurally complex drugs and chemical products. The company raised CHF1.8 million following a convertible loan in 2023 and plans to use the funds to improve its measurement technology, expand the team, and forge collaborations. Management says the capital will support go‑to‑market acceleration, talent acquisition across engineering, science, business, and sales, and strategic partnerships with pharma and academic institutions. ENANTIOS positions its approach as a way to remove critical bottlenecks in traditional drug development workflows.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jun 2024